...over wild-type FGF18. Merck KGaA (Xetra:MRK) has completed Phase II testing of recombinant FGF18 sprifermin (AS902330...

...Other companies are also working on growth factor-based therapies to promote cartilage production. Merck KGaA’s Sprifermin...

...the Phase II FORWARD trial to treat osteoarthritis (OA) of the knee showing that sprifermin (AS902330...
...of 100 μg sprifermin every 6 or every 12 months. Compared to placebo, the higher sprifermin...
...a recombinant human fibroblast growth factor 18 (FGF18). Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Sprifermin (AS902330...

...from the Phase II FORWARD trial to treat osteoarthritis of the knee showing that sprifermin (AS902330...
...of 100 μg sprifermin every six or every 12 months. Compared to placebo, the higher sprifermin...
...authorities to determine next steps. Sprifermin is a recombinant human fibroblast growth factor 18 (FGF18). Allison Johnson AS902330 Sprifermin Merck...

...KGaA 's Merck Serono S.A. unit also is pursuing disease-modifying therapeutics in OA. Merck Serono's sprifermin...